Hiv vaccine immunogens
AssigneesThe Rockefeller University, California Institute of Technology
InventorsMichel Nussenzweig, Pamela J. Bjorkman, Amelia Escolano, Harry Gristick
Life of this patent
Estimating the term…
Abstract
This disclosure provides HIV immunogens and use thereof for generating an immune response in a subject. Also disclosed is a method of isolating anti-HIV antibodies and use thereof. This disclosure further provides a method for treating or preventing a human immunodeficiency type 1 (HIV-1) infection in a subject using the disclosed HIV immunogens and/or antibodies.
Claims25
An isolated polypeptide having a peptide sequence that is at least 75% identical to a sequence selected from the group consisting of SEQ ID NOs:
- 2, 4, 6, 8, 11, and 13, wherein the polypeptide comprises substitutions at the positions corresponding to N133, N137, and N156 of SEQ ID NO:
- 1.
An isolated anti-HIV antibody, or antigen-binding portion thereof, comprising a complementarity-determining region having a sequence that is at least 75% identical to a polypeptide sequence listed in Tables 4, 5, 6, 7, 9, 10, and 11.
Dependencies are inferred from the claim text.